Perrigo licenses OTC rights to Merck's Nasonex

9 August 2018 - Deborah Wilkes

Premium

Perrigo has agreed a licensing deal for the prescription-to-OTC switch of Merck & Co's allergy medicine Nasonex Nasal Spray (mometasone furoate monohydrate) in the US. The company said the deal would create an "innovative product offering" for Perrigo, which specialises in store-brand products in the US.

Click tags below for more information on topics:

Perrigo

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: